Giant ocular surface squamous neoplasia managed with interferon alpha-2b as immunotherapy or immunoreduction.

@article{Kim2012GiantOS,
  title={Giant ocular surface squamous neoplasia managed with interferon alpha-2b as immunotherapy or immunoreduction.},
  author={H. Jane Kim and Carol L. Shields and Sanket U. Shah and Swathi Kaliki and Sara E. Lally},
  journal={Ophthalmology},
  year={2012},
  volume={119 5},
  pages={
          938-44
        }
}
OBJECTIVE To evaluate the efficacy of interferon alpha-2b (IFNα2b) for extensive ocular surface squamous neoplasia (OSSN). DESIGN Retrospective, interventional case series. PARTICIPANTS Eighteen eyes in 18 patients. METHODS Each patient with giant OSSN (a single tumor ≥15 mm basal diameter or ≥6 limbal clock-hours) was managed with topical IFNα2b (1 million IU/ml) 4 times daily or with injection IFNα2b (a portion of 10 million IU/ml vial) with follow-up every 1 to 3 months. MAIN OUTCOME… Expand
Treatment outcome with interferon alpha 2b in ocular surface squamous neoplasia: Recommendation as primary treatment by peripheral ophthalmologists
TLDR
In view of excellent treatment outcome and few side-effects, interferons can be considered as a primary, safe, and cost-effective treatment option for OSSN not only in tertiary centers but also by peripheral ophthalmologists. Expand
Topical Interferon Alpha-2b for Treatment of Noninvasive Ocular Surface Squamous Neoplasia with 360° Limbal Involvement
TLDR
Topical recombinant IFNα2b appears to be an effective alternative treatment for OSSN with 360° limbal involvement and precludes the high risk of limbal stem cell deficiency which results from surgical excision or topical chemotherapeutic agents. Expand
Interferon Alfa 2b for Ocular Surface Squamous Neoplasia: Factors Influencing the Treatment Response
TLDR
Interferon alfa 2b is an effective immunotherapy agent for tumors ≤6 clockhours of ocular surface in 82% cases and serves as an immunoreducing agent for larger tumors involving >6 clock hours of OSSN in 26% cases. Expand
Topical chemotherapy for giant ocular surface squamous neoplasia of the conjunctiva and cornea: Is surgery necessary?
TLDR
Topical chemotherapy was a safe and effective treatment, inducing complete regression in all cases of giant OSSN in this series, and there were no sight-limiting complications. Expand
Recombinant interferon alpha 2b for ocular surface squamous neoplasia: An efficient and cost-effective treatment modality in Asian Indian patients
TLDR
INF α2b is a cost-effective treatment modality for OSSN at an average total treatment cost of INR 9164 ($US 137) per patient and can be used for immunoreduction, immunotherapy, or immunoprevention of O SSN. Expand
Interferon for Ocular Surface Squamous Neoplasia in 81 Cases: Outcomes Based on the American Joint Committee on Cancer Classification
TLDR
IFN&agr;2b, when appropriately combined with surgical excision for OSSN, provides complete control in 95% of cases overall, specifically in 90% Tis, in 100% T1, in100% T2, in 94% T3, and in 100%, T4. Expand
Primary treatment of ocular surface squamous neoplasia with topical interferon alpha-2b: Comparative analysis of outcomes based on original tumor configuration
TLDR
Topical IFNα2b alone shows excellent overall tumor control of 95% with no difference in efficacy based on tumor configuration. Expand
Treatment of Ocular Surface Squamous Neoplasia with Interferon Alpha-2b
TLDR
Intralesional / peri-lesional Interferon(IFN)  Alpha-2b was given to the patients weekly along with interferon Alpha- 2b topical drops four times daily, for three months, with low recurrence rates. Expand
Risk factors for ocular surface squamous neoplasia recurrence after treatment with topical mitomycin C and interferon alpha-2b.
TLDR
Topical MMC and interferon alpha-2b are an effective treatment method for a wide range of noninvasive OSSNs and should be considered as primary therapy and avoided the morbidity of excisional surgery. Expand
The regression time of ocular surface squamous neoplasia using topical interferon alfa-2b does not depend on the initial tumor size.
PURPOSE The aim of this study was to determine if the initial tumor size correlates with the time to regression after topical interferon alfa-2b (1 million IU/mL) therapy in the treatment of ocularExpand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 41 REFERENCES
Topical interferon alfa-2b for the treatment of recalcitrant ocular surface squamous neoplasia.
TLDR
Topical IFN-alpha2b is an important treatment modality for recalcitrant OSSN; it avoids the risks of further limbal stem cell destruction from other agents and surgical excision. Expand
Treatment of conjunctival and corneal intraepithelial neoplasia with topical interferon α-2b
TLDR
The role of topical interferon alfa-2b (IFNα2b) in the treatment of conjunctival and corneal intraepithelial neoplasia (CIN) is evaluated and one patient was retreated, resulting in clinical resolution within 6 weeks, and has been tumor free for 8 months of follow-up. Expand
Treatment of conjunctival and corneal intraepithelial neoplasia with topical interferon alpha-2b.
TLDR
The role of topical interferon alfa-2b (IFNalpha2b) in the treatment of conjunctival and corneal intraepithelial neoplasia (CIN) is evaluated and one patient was retreated, resulting in clinical resolution within 6 weeks, and has been tumor free for 8 months of follow-up. Expand
Topical interferon alpha 2b eye-drops for treatment of ocular surface squamous neoplasia: a dose comparison study
TLDR
There were no significant differences in the effectiveness and side-effect profile of two doses of interferon alpha2b eye-drops in the treatment of ocular surface squamous neoplasia (OSSN), and topical therapy was well tolerated. Expand
Perilesional and topical interferon alfa-2b for conjunctival and corneal neoplasia.
TLDR
IFN alpha 2b may be a viable medical alternative to surgical excision for primary or recurrent CIN and is presented as a series of six patients who were treated successfully with a combination of subconjunctival/perilesional and topical IFNalpha 2b. Expand
Subconjunctival/perilesional recombinant interferon α2b for ocular surface squamous neoplasia: a 10-year review.
TLDR
Perilesional subconjunctival recombinant interferon α2b may be a viable medical alternative for the treatment of OSSN and future studies will be needed to evaluate the ideal treatment regimen of IFNα2b. Expand
Regression of Presumed Primary Conjunctival and Corneal Intraepithelial Neoplasia With Topical Interferon Alpha-2b
TLDR
Topical interferon alpha-2b alone may be an effective treatment of primary CIN and appears to be a safe alternative to radiation, intralesional IFN&agr;2b injection, and surgical excision with cryotherapy. Expand
Ocular Surface Squamous Neoplasia (Squamous Cell Carcinoma) of the Socket: Management of Extensive Tumors With Interferon
TLDR
Combined topical and injection IFNa2b could represent a potentially effective therapy for this condition and patients wearing ophthalmic prosthesis over a socket should be monitored for the development of OSSN. Expand
Treatment of conjunctival squamous neoplasias with interferon alpha 2ab.
TLDR
The absence of serious side effects after topical administration of INF alpha 2b leads to the recommendation of this modality of therapy for primary and recurrent cases of CIN. Expand
Treatment of ocular surface squamous neoplasia with Mitomycin C
TLDR
MMC treatment following surgical excision appears to decrease the recurrence rate of localised CCIN and should be considered as adjuvant therapy in primary treatment, and MMC should also be considered in the treatment ofLocalised recurrent disease. Expand
...
1
2
3
4
5
...